This conference call transcript was computer generated and almost certianly contains errors. This transcript is provided for information purposes only.EarningsCall, LLC makes no representation about the accuracy of the aforementioned transcript, and you are cautioned not to place undue reliance on the information provided by the transcript.
spk04: Good morning. My name is Gretchen, and I will be a conference operator today. At this time, I would like to welcome everyone to the Harmony Biosciences Third Quarter 2022 Financial Results Conference Call. All participant lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you'd like to ask a question at that time, please press star 1 on your telephone keypad. Please be advised that today's conference may be recorded. Lastly, if you should require operator assistance, please press star zero. I will now turn the call over to Louis Semay, head of investor relations. Please go ahead. Louis Semay, head of investor relations.
spk11: Thank you, operator. Good morning, everyone, and thank you for joining us today as we review Harmony Biosciences third quarter 2022 financial results and provide a business update. Before we start, I encourage everyone to go to the investor section of our website to find the materials that accompany our discussion today, including a reconciliation of our GAAP to non-GAAP financial measures. At this stage of our lifecycle, we believe non-GAAP financial results better represent the underlying business performance. Our presenters on today's call are John Jacobs, President and CEO, Dr. Jeff Friedano, Chief Medical Officer, Jeffrey Dirks, Chief Commercial Officer, and Sandeep Kapadia, Chief Financial Officer. Moving on to slide two. As a reminder, we will be making forward-looking statements today, which are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties. Our actual results may differ materially, and we undertake no obligation to update these statements, even if circumstances change. We encourage you to consult the risk factors referenced in our SEC filings for additional details. I would now like to turn the call over to our CEO, John Jacobs. John?
spk08: Thank you, Louis, and thank you, everyone, for joining our conference call today. We delivered another strong quarter in Q3 as we continued to execute on our three-pillar growth strategy, and we are excited about the momentum we see in the business, positioning us well for the remainder of the year. I would now like to highlight our progress on each of the three pillars of our growth strategy in the context of Q3 2022 performance, or on slide three. Starting with pillar one, which is to optimize the commercial performance of WCAG. In Q3 2022, we delivered another strong quarter for WCAG, with net sales of $117.2 million, a 45% year-over-year increase for the quarter. Our performance reflects the continued demand for WAKIX and the significant unmet need that remains in the narcolepsy market. For the remainder of the year, we expect continued growth for WAKIX, and we believe that the vast market opportunity which remains in narcolepsy provides us with the opportunity to grow WAKIX for years to come. Let's move on to Pillar 2, which is to expand the clinical utility of WAKIX beyond narcolepsy. This morning, we announced top-line results from our Phase II proof-of-concept study in patients with Prader-Willi syndrome. Top-line data showed a positive signal on the primary outcome of excessive daytime sleepiness, and we intend to advance this clinical program in PWS. Dr. Jeff Dana will provide more details on the top-line study results later in the call. We also continue to make excellent progress on our Phase III in-tune study for wakeks and idiopathic hypersomnia, or IH. This opportunity, if successful, could be the next potential indication for WCAGS. The IH opportunity is synergistic with our existing expertise and infrastructure with the same HCP call universe as narcolepsy, which will allow for significant efficiencies for the launch if we succeed. We are excited with the continued advancement of our pipeline programs and are hopeful that these efforts could lead to additional indications for WCAGS. And finally, Pillar 3, acquiring new assets through business development to expand our portfolio beyond WCAG. In late September, we closed our new agreement with Buyer Prejet, which will enable us to pursue new therapeutics based on pitulicin for the treatment of narcolepsy and potentially other indications mutually agreed to by the parties. If successful, these efforts could expand Harmony's franchise in narcolepsy and potentially other indications by yielding one or more new products with the potential to launch during the WCAG lifecycle. We look forward to providing additional updates as we advance these efforts. As we have said before, we began our business development efforts early in our company history so we could take the time to be thoughtful and prudent in what we acquire and flexible in the types of transactions we're able to consider. Over time, our intention is to develop a broad portfolio of rare orphan neurology assets and or assets in other neurological diseases where we can leverage our existing expertise and infrastructure. To achieve this, we intend to leverage our strong financial position to acquire additional assets over time and across a range of development stages, including both early and later stage, with the potential to launch both during and after WACIC's lifecycle. We are in a solid position to execute on Pillar 3 as our business fundamentals with Wakex remain strong. We had approximately $316 million in cash, cash equivalents, and investment securities as of Q3, and we anticipate that we will continue to generate cash moving forward. Overall, I'm extremely pleased with the progress on our three-pillar growth strategy. We remain confident in WCAG being a potential $1 billion-plus franchise in the coming years via narcolepsy and additional indications. And with that as a foundation, I am truly excited about what we can achieve next at Harmony. I would now like to turn the call over to Jeff Dirks, our Chief Commercial Officer, to provide more details on our commercial performance. Jeff?
spk09: Thanks, John. We continue to see strong momentum in our business and made significant strides in the third quarter of 2022, both in net revenue and underlying business fundamentals shown on slide four. Net revenue for the third quarter was $117.2 million, which represents a 45% increase from the same quarter of previous year. We're also pleased with the 10% sequential growth in the second quarter of 2022, demonstrating continued strong performance and growth in the adult narcolepsy market. I'd like to take a moment to highlight a few of our underlying business fundamentals on slide five that drove our performance in Q3 2022. The average number of patients on WAKIX increased to approximately 4,600 in the third quarter. The growth in Q3 reflects the continued strong underlying demand for WAKIX, building upon the strong second quarter we saw earlier this year. Q3 top line prescription demand New patient starts and refill behavior remain strong through the typical summer seasonality, in part due to the following factors. First, Harmony Field Sales in-person engagement with healthcare professionals and their office staff increased in the third quarter. Approximately 85% of all Harmony Field Sales engagements with healthcare professionals and their office staff were in-person in Q3, an approximate 10% increase from the previous quarter. The increase in access allowed for further education and engagement with healthcare professionals on the meaningfully differentiated product profile of WCAGS and provided an opportunity for our expanded field sales team to drive WCAGS growth in both new and existing prescribers. Second, the WCAGS prescriber base continued to grow. We saw growth in new writers of WCAGS as well as growth in prescribing from existing WCAGS writers. Growth in new prescribers continued to come from writers of traditional narcolepsy treatments, as well as healthcare professionals who've been reluctant to prescribe other available scheduled narcolepsy treatments. Existing prescribers continued to find new adult patients with narcolepsy in their practices for wake-ups, both naive patients as well as existing patients currently on other treatments with residual symptoms of excessive daytime sleepiness or cataplexy. The continued growth in both the depth and breadth of our prescriber base demonstrates the broad clinical utility of WAKIX and what we believe is a significant opportunity for growth in the years to come for WAKIX and adult narcolepsy. Recent market research conducted by Harmony with approximately 70 narcolepsy-treating healthcare professionals reinforces our belief and demonstrated strong intent to increase future prescribing of WAKIX. The vast majority of WCAG writers surveyed expressed intent to increase their prescribing of WCAG and cited the patient satisfaction and positive feedback on treatment as a primary driver. And lastly, we saw the impact of our field sales force expansion. Our expanded field sales team that was in place at the beginning of the second quarter extended the reach and frequency of our educational outreach among narcolepsy-treating healthcare professionals in the third quarter. The increase in in-person access coupled with greater reach and frequency in our education, help to drive new patient starts among new and existing prescribers. We are excited about what we're seeing from our award-winning sales team and the difference they're making in the narcolepsy community. In summary, we believe our continued strong performance highlights the large remaining opportunity in narcolepsy. We're beginning to see an anticipated rhythm to our business. and we continue to tap into this opportunity as the market allows around the typical seasonal dynamic that the pharmaceutical industry as a whole experiences each year. The strong performance and solid underlying business fundamentals of WACICS affirm our confidence in the future growth opportunity for WACICS and adult narcolepsy and reaffirms our belief that WACICS is a potential billion-dollar-plus franchise opportunity in narcolepsy and other additional indications. I'll now turn the presentation over to Dr. Jeff Dano for an update on our clinical development programs. Jeff?
spk10: Thank you, Jeff, and good morning, everyone. I will provide an update on Pillar 2 of our company growth strategy to increase the clinical utility of Pitocin toward potential new indications in additional patient populations living with rare neurological diseases. This morning, we announced promising initial top-line data from our Phase II PRUPA concept trial in patients with Prader-Willi syndrome, or PWS. On behalf of Harmony, I would like to thank the patients with PWS and their families who participated in this clinical trial. As shown on slide 6, This trial was a randomized, double-blind, placebo-controlled study designed to assess the safety and efficacy of Pitocin in patients with PWS. This proof-of-concept study was not powered to demonstrate statistical significance, but rather was designed for signal detection. The study included patients ages 6 to 65 years who were evenly randomized in a one-to-one-to-one fashion to low-dose pitolicin, high-dose pitolicin, or placebo treatment groups. Pitolicin dosing was based on three age cohorts, children 6 to less than 12, adolescents 12 to less than 18, and adults 18 to 65. And another objective of the study was to evaluate for a dose response to Pitocin in patients with PWS. The primary endpoint of the study was the evaluation of Excessive Daytime Sleepiness, or EDS, as measured by change from baseline to end of treatment on the Effworth Sleepiness Scale for Children and Adolescents, referred to as the ESS-CHAD parent-caregiver version of the scale. The demographic data showed the following. A total of 65 patients enrolled in the trial. 91% completed treatment, and all but one patient opted to continue into the open label extension, which is ongoing. Mean age of the study population was 12 to 13, with 51% of the patients male and 49% female. Of the total study population, 52% were children, 29% were adolescents, and 19% were adults. The top line study results are summarized on slide seven. Mean baseline ESS-Chad scores ranged from 14.7 to 15.7, representing a moderate to severe degree of EDS at baseline. Mean change from baseline to end of treatment on the ESS-Chad scores ranged from negative 3.7 to negative 5.5 across all age groups and dosage groups, representing a clinically meaningful change in the active treatment groups, which is defined as a greater than or equal to two-point improvement on this scale as per the American Academy of Sleep Medicine treatment guidelines that were published in September 2021. In two of the three age groups, the children and adult groups, there was a clinically meaningful difference with a minimum of two points between pitocin and placebo driven by the high-dose pitocin treatment group. In the adolescent age group, there was a high placebo response of a magnitude three times that seen in the other two age groups. which resulted in the lack of a clinically meaningful difference between pitocin and placebo in this age group. Slide 8 shows the results of a responder analysis from the top-line data, which was defined as an improvement on the ESS-Chad parent-caregiver version of greater than or equal to three points or a score of less than or equal to 10 at end of treatment, which is a more conservative definition of response. Response rates were 70% in the high-dose pitocin group, 55.6% in the low-dose pitocin group, and 52.6% in the placebo group. Lastly, slide 9 shows a snapshot of the overall safety tolerability profile of pitocin seen in this trial, which was consistent with the known safety tolerability profile of pitocin. Adverse events were reported in 57% of patients on Pitocin and 65% of patients on placebo. Treatment-related adverse events were reported in 26% of patients on Pitocin and 30% of patients on placebo. The most common adverse events reported were anxiety, irritability, and headache. There was one serious adverse event in a patient in the placebo treatment group. In summary, we are encouraged with the top-line data which showed that treatment with Pitocin resulted in a clinically meaningful reduction in the ESS-Chad parent-caregiver scores in all age groups and across both low-dose and high-dose treatment arms, as well as a clinically meaningful difference from placebo in the children and adult subgroups. The tolicent was well tolerated in this clinical trial with an overall safety tolerability profile that is consistent with the known safety tolerability profile of the tolicent. Looking ahead, we expect to receive the full data set before the end of the year, which will include the results on the secondary outcomes, including caregiver and clinician global impression scores, as well as measurements of behavioral symptoms, cognitive function, and hyperphagia. The positive signals observed on the primary outcome of EDS from this proof of concept study are promising, and we look forward to receiving the full data set from this initial signal detection study, which will further inform our understanding of the data as we plan to advance our clinical development program for Pitocin in patients with PWS. In the meantime, I want to thank our clinical investigators and their teams who partnered with us in the conduct of this trial. as well as the patients with PWS and their families who participated for whom we are grateful. As we know, there are limited therapeutic options available for people living with PWS, resulting in a significant unmet medical need. Turning to our other clinical development programs shown on slide 10, we have made significant progress on those as well. starting with our development program in idiopathic hypersomnia, or IH, which we are very excited about. After initiating our Phase III registrational trial in adult patients with IH in April, known as the InTune study, we are seeing very good momentum in patient enrollment, with over 70% of our planned clinical trial sites being active. If this Phase III trial is successful, it could represent the next new indication for WAKETS in adult patients with IH. Moving on to our development program in myotonic dystrophy or DM. Enrollment continues in our phase two proof of concept study in adult patients with type one myotonic dystrophy or DM1. We have activated sites in Canada in areas where there is a large population of patients with DM1. We anticipate top line data from this phase two proof of concept study in 2023 and we'll provide an update on the timing of this data readout early next year. Finally, with regard to pediatric narcolepsy and a pediatric indication for WCAGS, our partner BioPregé completed a phase three trial in pediatric narcolepsy patients. BioPregé submitted the data to the EMA second quarter this year, seeking approval for a pediatric narcolepsy indication. EMA's decision on BioPregé's pediatric narcolepsy submission is anticipated early next year, which could help inform our strategy related to submission of this data to FDA. In the meantime, we are committed to obtaining pediatric exclusivity for WCAGS and submitted a request for a Pediatric Written Request, or PWR, during the third quarter. We will provide an update on our interactions with FDA related to this request once we hear back from them. To conclude, we have made significant progress in advancing our clinical development programs at Harmony. We are encouraged by the initial top line data from the PWS phase two proof of concept study and the positive signal that was generated for EDS. We look forward to learning more when the full data set is available later this year. after which we will request an end of phase two meeting with FDA. Our plan is to present the findings at a future medical meeting and submit the full results for publication to a scientific journal. For IH, we are very excited about the interest and momentum we are seeing in our in-tune study of phase three registrational trial in adult patients with IH. We continue to appreciate all the effort to the clinical investigators and their teams who are partnering with us in the conduct of this trial and the interest from the IH patient community. If this Phase III trial is successful, it could represent the next new indication for WCAG in adult patients with IH. I will now turn the call over to our CFO, Sandeep Kapadia, for an update on our financial performance. Sandeep?
spk08: Thank you, Jeff, and good morning, everyone. This morning, we issued our third quarter 2022 press release and filed our 10Q where you'll find the details of our financial and operating results. Our third quarter performance is also shown on slides 11, 12, and 13. We experienced yet another strong quarter of performance with year over year growth across several of our key metrics. We're pleased with our year to date performance and the momentum we're seeing for the remainder of the year. For the third quarter of 2022, we reported net revenues of $117.2 million compared to $80.7 million in the prior year quarter. This represents a growth of 45% and reflects the strong underlying demand for WCAG. In the third quarter of 2022, operating expenses were $82.3 million compared to $45.1 million in the prior year quarter. The higher operating expenses were primarily driven by the $30 million initial licensing fee, part of the new agreement with Bioprojet, as well as our ongoing commercialization of WCAG and patient enrollment in our clinical trials. Operating income for the third quarter was $11.9 million, compared to $21.1 million, a 43% decrease versus the prior year quarter. However, excluding the one-time $30 million initial licensing fee, operating income almost doubled versus the prior year quarter. In the third quarter of 2022, we released the valuation allowance on our deferred tax asset, resulting in a one-time $74.5 million income tax benefit for the quarter. The release was driven by our history of profitability. which is a positive indicator of our ability to realize the value of the deferred tax asset in future periods. Non-GAAP adjusted net income for the third quarter was $58.1 million, or $0.95 for diluted share, compared to $23.4 million, or $0.41 for diluted share, in the prior year quarter. We believe non-GAAP adjusted net income better reflects the underlying business performance Please see our press release for a reconciliation of this measure. During the third quarter of 2022, we generated approximately $55 million in cash from operations and ended the third quarter with $316 million of cash, cash equivalents, and investment securities. As a reminder, the $30 million initial licensing fee to Viaprojet was incurred in the third quarter but will be paid in the fourth quarter. Looking ahead, we expect quarter-over-quarter net revenue growth for Q4. We also expect to see increase in ongoing investments in R&D SG&A as we continue enrollment in our Phase III IH registrational trial and continue commercialization of WCAGs. In conclusion, our strong performance with Wakex and the resulting cash generation is enabling Harmony to make important investments in our business while maintaining profitability and adding to our strong cash balance to execute on our three-pillar growth strategy. And with that, I'd like to turn the call back to John for his closing remarks. John? Thank you, Sandeep. So in summary, our strong performance positions us well to execute on our three pillar growth strategy. Based on the year-to-date results and demand trends we're seeing for WCAG, we're confident that 2022 can be our best year yet in company history. Our intent is to continue growing WCAG sales in narcolepsy via good commercial execution and strong organic demand for this unique and meaningfully differentiated product. to continue to advance our clinical programs with the goal of expanding the utility of wakex beyond narcolepsy to help bring this innovative therapy to new patient populations and to continue to acquire new assets beyond wakex to develop a broad portfolio of rare orphan neurology assets and or assets in other neurological diseases where we can leverage our existing expertise and infrastructure we look forward to updating you on our progress this concludes our planned remarks today Thank you for joining our call. And I will now turn things back over to the operator to facilitate the Q&A session. Operator, can we please open the call to questions?
spk04: Thank you. At this time, if you'd like to ask a question, please press star 1 on your telephone keypad. If you wish to remove yourself from the queue, you may do so by pressing star 2. We remind you to please pick up your handset and please limit yourself to one question and one follow-up question. We'll take our first question from Frances from Oppenheimer.
spk02: Hi, thanks for taking the question. Congrats on a strong quarter here. So just in terms of both the quarter and the data, so maybe just on PWS, or just to be clear, EDS for PWS at the start. The placebo response in the adolescent, is that something that, you know, you guys have thoughts about why that might have been so strong? And just, I know it's dangerous to cross compare, and this was not powered for STAT-SIG, but just looking at your previous trials, is there maybe... Maybe an expectation that with this patient population, placebo response might be higher than the narcolepsy patient population. Thanks.
spk08: Jeff Bainer, you want to take that?
spk10: Sure. Yeah. Good morning, Frank. Thanks for the question. With regards to, yeah, the placebo response in the adolescent group, so first of all, it's a bit too early to tell, you know, what's happening there without having seen all the data yet. The first thing in terms of we know that that group, if you look at the numbers, it's a small N in that group. There were nine patients. So there's potential for greater variability. We also saw just in the top line data that there was one outlier in that group. So given the outlier and the small N driving some of that variability. With regards to placebo response in the other age groups, in the children and in the adults, they were consistent with what we saw in the narcolepsy trials. So we will obviously be looking into that further. The one other thing, too, is that when we have the PK data, we'll be able to look at PK PD correlation exposure response. But, you know, overall, we're very encouraged by, you know, the overall data in terms of movement on the ESS, you know, in all of the age groups and in both dosage groups, you know, more than two points showing a clinically meaningful change in the ESS, you know, as well as the separation of clinically meaningful difference, you know, in the children and the adults. And we'll look at that, you know, the placebo outlier in the adolescent group, and we have the full data set.
spk02: Okay.
spk08: That's very helpful. And this is a tough patient community to treat. As you know, there's been many, many struggles to try to get therapies for patients in this group. So the patient community is encouraged so far with what we've seen, and so are we.
spk02: Okay, great. And I'll take the operator up on a follow-up question. So just any issues? I'm just wondering, as the sales keep picking up steadily, have you seen any issues with reimbursement in terms of patients that might also be on an oxibate, or has that not been an issue? And do you ever break down what percentage you think of patients are actually on both pitulicin and oxibate and whether or not that percentage is growing? Thank you.
spk08: Thanks, Frank. Jeff Dirks, you want to take that one?
spk09: Sure. Thanks for the question, Frank. So what we've seen is really strong favorable market access really since very early in our launch, Frank. So we haven't seen any challenges with respect to reimbursement and getting coverage for WCAG patients across commercial Medicare or Medicaid. When you're looking at patients that may be concomitantly on both pitolosan and sodium oxibate, it's a relatively low percentage. What we've shared publicly, it's low double digits, Frank. And given that this is a rare orphan patient community and you've got a small percentage of these patients and they're spread out over about 125 different managed care accounts, we have not seen any challenges in these small cohorts of patients on both oxibate and WACIX continuing to get reimbursement for treatment.
spk02: Okay, thank you very much. That's it for me.
spk04: Our next question comes from David Absalon from Piper Sandler.
spk00: Hey, thanks. So just a couple. First, can you comment, and I apologize if I missed this, on patient persistence? And I'm wondering in particular how that has changed, if at all, as you're seeing more and more patients regularly see doctors in person. So talk about that and particularly persistence in the context of other wakefulness-promoting agents, such as Oxibate and Modafinil. So that's number one. And then secondly, you know, you've talked a lot about business development in M&A. I know you've got a lot of questions about it, but I wanted to ask something a little more. targeted, which is your appetite for adding a late-stage asset or even a commercial-stage asset where you can in some way leverage the commercial infrastructure you had in place. And to the extent you do something that's sort of a larger size, how large can you go in terms of capital allocation? Thank you.
spk08: All right, Jeff Dirks, why don't you take the first question, and I'll take the second one. Sure.
spk09: So, David, with respect to patient persistency, what we've disclosed publicly is that you continue to see discontinuation rates of drugs in this entire category range between 30% and 50% at 12 months. And consistent with other chronic medications, there usually is an additional discontinuation rate after the first year. It's at a much lower rate. But it does continue over time. But what we've actually seen recently, and it probably doesn't come to any surprise and certainly doesn't come as surprise to some of the healthcare professionals, is as we're coming out of the COVID time period and as we're getting greater engagement between patients and their healthcare professionals, we have seen a slight increase. in improvement in the discontinuation rates among all of these products. Now, healthcare professionals tell us that WCAG's DC rate is consistent with other products in this category. Their perception is it's a little bit better than what they're seeing with some of their other traditional medicines. And we're seeing great, you know, persistency. For those patients that stay on the drug, about 90-plus percent of patients are compliantly taking the drug every day as prescribed by their doctor. So extremely pleased by what we're seeing in the marketplace, the receptivity of the product and patient feedback.
spk08: Yep, and then David, your second question that absolutely we're open to later stage assets and assets that may already even be revenue generating. As we said all along, we started this journey in business development very early in our company history so we could be very prudent and choiceful in what we acquire with a distinct focus on what we know how to do well at Harmony, rare orphan neural and or neurology where we can leverage our strong and proven successful infrastructure and experience base in this arena. And so that absolutely includes later-stage assets. In fact, our desire is to build a portfolio of both early-stage and later-stage assets that has the potential for product launch both during and post-Waitex lifecycle. And finally, we're in a very good position on capacity. Sandeep, did you want to address our capacity for doing deals? Sure. As you mentioned, John, we're in a very strong position. At the end of the last quarter, we had $316 million On the balance sheet, as you also saw, we had a really strong cash generation, $55 million this past quarter we generated from operations. And, of course, we continue to have access to capital, whether it be the additional debt capital. We have still a $100 million shelf at Blackstone that we certainly pull on. And then, of course, we can also access the public market. So I think, you know, we have a lot of optionality in terms of capital allocation. Thank you, Shandi. Thank you, David. Thank you.
spk12: Thank you.
spk08: Operator, any additional questions? Do we still have connectivity on the line? We do.
spk11: Hey, Gretchen?
spk04: Yes. Our next question comes from Charles Duncan from Panther Fitzgerald.
spk12: Super. Hopefully you can hear me. John and team, congrats on a great quarter. So I had two questions, one commercial, one pipeline. With regard to the commercial question, I guess I'm wondering if Jeff or John could speak to the current field, Salesforce. I guess I'm wondering if you feel like with the incremental growth in it, do you feel like it's optimized? And would you consider I think you mentioned that you are, I guess, fully understanding the rhythm in your business. So does that point to possible guidance for next year?
spk08: Yeah, Jeff, why don't you address the Salesforce component, and then Sandeep can address our thoughts around guidance. Go ahead.
spk09: Sure. Now, great question, Charles. Thanks very much for asking. So our field sales team, we have 77 individuals in the field. And, Charles, we do believe and feel that it is optimized for the current adult narcolepsy opportunity. We're calling on about 9,000 healthcare professionals. And given what we saw earlier in this year about the broadening of the prescriber opportunity outside of those Oxibate, Rems, and Roll doctors for physicians that traditionally did not prescribe scheduled medicine, we added 10% more to our field sales team. What we saw in the third quarter is with greater openness, and engagement, we were able to increase the reach and frequency of our healthcare professionals, which really helped to drive new patient starts in both new and existing prescribers. And one of the other things, Charles, that we've also done to help augment our current in-person field sales team is what we learned through COVID is that there is always going to be an element of telemedicine and virtual detailing that's going to exist in healthcare professionals' practices. We have engaged an inside sales rep or a remote healthcare professional outreach team. So we've increased that group to six individuals that are starting in the fourth quarter of this year. That helps us reach some of the white space areas where there may not be a representative aligned to a health care professional. It helps us provide greater reach and frequency to some of the urban areas in our territories, and it also allows for us to continue to engage with health care professionals should we see a vacancy in a territory, which really helps make sure that the patient and the health care professional community continue to get supported from Harmony during those times. So hopefully that helps. Thank you. Yes. Thank you.
spk08: Yeah, and with respect to guidance, as you mentioned, I mean, next year would be the natural point where we would certainly consider. I can't really provide guidance on guidance at this stage, but, you know, but generally that would be the point that we would consider. I think we've got a good history of proven success over our launch. We have a good cadence there. You know, we're pleased with the overall performance and, you know, see continued growth opportunity as, you know, as John mentioned, continue to see Wayfix as a billion-plus franchise in the coming years with narcolepsy and other indications. So, you know, more to come. We'll update you, you know, as we go into next year. Thank you, guys. Thank you, Charles.
spk12: Can I ask a question on the pipeline? Sure. Okay, super. So just quickly, With regard to the PWS results, nice to see, know that you're waiting for some additional details. But I guess I'm wondering if you could speak to what you would like to do. Could you anticipate moving into next stage of development next year, and could that be pivotal? And then is there any way to provide information on how many of the patients or percentage roughly are decided to continue in the open label extension.
spk08: Go ahead.
spk10: Yeah, sure, Charles. Good morning. So in terms of, you know, our plan, I think that, you know, we're encouraged by the positive signals that we've seen from the top line data. And obviously, the next step is to look at the full data set, you know, which will further inform our understanding around the data. And then, you know, it's our intent to request an end of phase two meeting with FDA. as we do plan on advancing, you know, our clinical development program for Pitocin and Prader-Willi syndrome. So, obviously, next steps, you know, look at the full data set, inform the strategy of approaching FDA and a Phase II meeting, and then plan to go into a pivotal Phase III trial. With regards to the last part of your question, we saw that, you know, 65 patients were enrolled in the trial. Ninety-one percent completed the treatment, and all but one patient opted to go into the open-label extension. So the majority of the patients that completed went into the open-label extension, and that's what we saw from, you know, the initial top-line data.
spk08: Very good. We're excited about this data, especially on behalf of the patients and the caregivers and all the KOLs and folks who worked with us to do this. This is a community who really needs therapeutic options. Dr. Gaynor and his team really did a great job leading us through the COVID pandemic, all the challenges to complete a clinical trial on time. Jeff, like you and your team did, you should be really proud of this accomplishment on behalf of patients. And it is our intention to make this program work. into a phase three, but as Dr. Dano says, next step as opposed to phase two. And we look forward to keeping you posted.
spk10: And Charles, just those numbers. So, yes, 65 enrolled, 59 completed the treatment, and then 58 of the 59 went into open-label extension, and that is ongoing.
spk12: Excellent.
spk10: Thanks for the update.
spk04: Our next question comes from Corrine Jenkins from Goldman Sachs.
spk12: Hey, Corrine.
spk03: Good morning. Yeah, good morning. So I think it looks like gross to net has improved pretty considerably year over year. I think list price is up 5%. It looks like net revenue per patient is up about 10%. So could you talk about what you're seeing with respect to gross to net and how we should expect that to continue moving forward? And also just if there's any impact of stocking on what that looks like in this quarter?
spk08: Yeah, hi, Corinne. In terms of gross to net, I mean, as you know, gross to net increases typically in the first quarter and then relatively stable for the balance of the year. What we've seen is a similar evolution this year as well. Versus last year, we did have a price increase earlier this year, so you'd have to see a net price increase over last year. But generally, growth has been relatively stable for quarter two and quarter three. Jeff Dirks, any additional color you want to add to that?
spk09: Sure, Kurt. One other thing, when you're kind of looking at the average cost per patient, Just as a reminder, our patient assistance program demand has been relatively flat. So as we continue to add the average number of patients, we're starting to see a higher percentage of revenue-generating patients, which is likely reflective in the average cost per patient that you're seeing. So I thought that might be helpful as well as you're looking at your data. Yeah.
spk03: Yeah, that's really helpful. Thank you. And then maybe could you just contextualize the data that we saw in Crater-Willi Syndrome versus other weight-promoting agents that might be off-label in that population?
spk08: Dr. Gaynor, you want to take that one?
spk10: So, Corinne, I think that in terms of contextualized, so probably the reference with regards to what we saw with the Tolson in the narcolepsy studies, we see similar trends with regards to clinically meaningful change across all the age groups and both dosage groups, greater than two-point difference on the ESS. In terms of, you know, there's not a lot of data in terms of other way clinics agents use off-label and Prader-Willi, so it's hard for me to comment on that in terms of the other agents used off-label. There's no, you know, randomized controlled trials to, you know, give a frame of reference.
spk08: Yeah, well said, Jeff. There are a few very small studies, Corinne, maybe ISS and other things out there that just have no results. And I think just the general takeaway from that is that it's a very unsatisfied marketplace. There's a tremendous need for new therapeutic options. And as you know, a lot of companies have made valiant efforts to try to help these patients to no avail, and that's disappointing for everyone. Our industry and that patient population, we're very excited about and encouraged about these initial top-line results in this POC study right now.
spk04: Great. Thank you. Our next question comes from Chris Howerton from Jefferies.
spk12: Chris.
spk01: Hey, good morning. Thanks so much for taking the questions. I guess two, probably both for the Jeffs. On the commercial side, I guess I just wanted to better understand how you anticipated seasonality impacting the quarter. I think you signal ahead of time that you would have anticipated some headwinds to new patients due to the end of the summer. So I guess I just wanted to see, like, did you actually see that and what were your learnings you know, with respect to this quote unquote seasonality. And then on the pipeline question, you know, I guess what I'm curious is, is excessive daytime sleeping is an approvable endpoint for Prady-Willi syndrome? And, you know, what might be some other important clinical features in the eventual package to get a label in that indication? Thank you.
spk08: Thanks, Chris. Jeff Dirks, you want to take the first part of that?
spk01: Sure.
spk09: Good morning, Chris. Thanks for the question. So certainly we're extremely pleased with our performance in the third quarter of $117.2 million. And, you know, to put that into context, it was about a 10% increase from the second quarter. And as a reminder, our growth from Q1 to Q2 was 25%. So if you're looking at the relative rate of growth, Between those quarters, you can see it's reflective of the impact of that summer seasonality. As I shared in my prepared remarks, we did see a couple of strong drivers that helped to overcome and offset some of that summer seasonality. Obviously, we saw an increase in in-person engagement, which we know is very meaningful. We saw the impact of our expanded field sales team, and we also saw the continued growth in the depth and breadth of our prescriber base. And so we believe, obviously, our strong performance is really highlighting the large remaining opportunity in adult narcolepsy, and we are starting to begin to see that anticipated rhythm, right? You get typical seasonal dynamics in the first and the third quarter where rates of growth tend to be a little bit lower, followed by stronger traditional second and fourth quarters. And we're excited, obviously, about the growth opportunity for WACICS and moving forward, and we remain confident that this has an opportunity to continue to grow for years to come.
spk08: And the second part of the question.
spk10: Yeah. Yeah, Chris, good morning. So in terms of EDS as an approval indication in patients with Prader-Willi, so EDS is a common symptom in that patient population, you know, seen in over 50% of the patients. And, you know, based on, you know, our dialogue with FDA and this first signal detection study, you know, we believe it's an approvable indication that you know, with clinically meaningful data. So we're encouraged by the initial top-line results, and obviously, you know, we'll engage further with the agency towards designing a pivotal Phase III trial. In terms of the other symptoms, obviously, the Phase II proof-of-concept study, we're looking at other outcomes, as you're aware, you know, the behavioral symptoms, cognition, and hyperphagia. So we look forward to seeing, you know, those data and, you If the data supports clinically meaningful changes on those scales, then we would include that in terms of the design of the Phase III trial with regards to other symptomatic indications in a label. So I think that we will wait to see the full data set, and that will inform our approach with FDA and then the design of a Phase III trial.
spk01: Okay. All right. Well, very good. I appreciate you taking the questions, and congrats on the quarter again.
spk08: Thank you, Chris.
spk04: Our next question comes from Greg Zimbalmanabi from Mizo Securities.
spk06: Hey, good morning, team. How are you? Congrats on a great quarter. One of my questions is about the trends that you might be seeing for WCAG as you exit or as you've exited out of September and into October. Any color you can just provide for us. And I just wanted to get a – I think Jeff Dirks, you had mentioned this, but just get a confirmation on how you are viewing the fourth quarter in terms of the – I guess the seasonality of the fourth quarter being a stronger quarter. I just want to make sure that those comments still hold up, and then I've got a follow-up question. Thanks.
spk08: Yeah, Greg, obviously we're not providing forward-looking guidance, but we have said that we expect continued growth for the rest of this year on an objective, so if you want to add a little bit more color to that.
spk09: Yeah, I appreciate the question, Greg. And consistent with John, even though we can't speculate moving forward, we continue to see strong momentum in our business and top-line demand in new patient starts and refill behavior. And we do anticipate growth in all of our underlying business fundamentals moving forward quarter over quarter. That's probably about as much context as I can kind of give you. We're very confident in our ability to continue to grow this brand moving forward.
spk08: Yeah, and I think, Greg, overall context is important for the audience to understand, right, that there's 72,000 to 80,000 diagnosed narcolepsy patients in the U.S. with tremendous unmet need. that remains. And so we see a lot of long-term opportunity for WACIX to continue to penetrate this marketplace to help patients who are in need. The polypharmacy market, WACIX is often combined with other therapies to add synergistic benefit and help these patients. So we see potential growth for WACIX for years to come, and that's why we're confident in saying we see WACIX as a billion-dollar-plus franchise in narcolepsy and other indications in the years to come.
spk06: Okay. Thank you very much. And then, My final question just had to do with the data that you just shared with us in terms of the proof of concept phase two in Prader-Willi syndrome. I know that you're expecting to see the full data set and particularly data on some of the secondary endpoints. Is there anything in particular that you're trying to get an assessment of that really will help to inform kind of how you're thinking about the next steps or what the pivotal phase three or what the clinical trial design might be in terms of what's next for that program.
spk10: Dr. Dana, you want to take that one? Sure. Yeah, thanks for the question, Greg. In terms of the data set, obviously the primary focus is around excessive daytime sleepiness, you know, the tolicent mechanism of action, the mechanism-based approach to our life cycle management. So that's the primary focus where we had the most confidence. So the initial top line data readout and those signals that we're encouraged about. As a signal detection study and looking at other key symptoms as I alluded to just before, other symptomatology. So we'll look for signals on the behavioral aspect of this patient population. cognitive function, and then obviously hyperphasia as the cardinal symptom of, you know, PWS. So, you know, that full data readout will inform, you know, the overall aspect of the single detection study. And then based on those findings, you know, we'll inform our approach to design of a phase three trial. But really, primary focus is around excessive daytime sleepiness, and we're encouraged by the positive signals, you know, that we've seen in terms of movement on the ES at this scale across, you know, all the age groups and both dosage groups of Pitocin.
spk06: If I could have just one last follow-up question just on that. I think you mentioned that you would expect to share the full results at a medical conference. Is it fair to assume that this would be sometime in 2023, maybe first half of 2023?
spk08: We haven't provided timing, Greg, yet on a particular conference, but what we have said is that we expect to have the full data set prior to the end of the year.
spk06: Oh, okay. Thank you so much for that clarification.
spk08: You're welcome. Thank you, Greg.
spk04: The next question comes from .
spk13: Hello. This is Amin for AMI. Thank you for taking the question. I have a question on on the clinical trial results. So on the PWS patients, they're usually on polypharmacy. I wanted to know if you can add some color on whether there were any drug-drug interactions that you needed to change the prescriptions that that patients on the trial needed to take, and is there any rate on any changes on that, on their medication because of drug interactions? And also, you reported around 12% adversement, which is anxiety. Is there anything Anything that makes you confident that the level of anxiety would decrease in the open labial extension as you're not increasing the dose during this period?
spk10: So, I mean, with regards to drug-drug interaction, so the only FDA-approved drug for patients with Prader-Willi is growth hormone, and we know that they're on other medications for behavioral symptoms, et cetera. So there were no specific, in terms of drug-drug interactions, it's basically guided by the, you know, the label for Wakex with regards to the known drug-drug interactions of what was allowed and not allowed. But other therapies that they're on, you know, that don't have a known drug-drug interaction with Pitocin were allowed, you know, in the trial. In terms of the level of anxiety, the safety tolerability profile that we saw in the study is very consistent with the known safety tolerability of Pitocin in what we saw in narcolepsy as well as other clinical trials. And I think that's the initial data that we have. the open-label extension and longer-term exposure, you know, we'd be able to comment further on, you know, on that.
spk08: And just a comment, I mean, good question, actually, when it comes down to the practicality of using a drug to help patients who may be on polypharmacy. And in the narcolepsy space, as you all know, WAKIX can be safely added on to standard of care therapies. We have the drug-drug interaction data right in our label for the wake-promoting agents as well as sodium oxibate products. So that's one of the benefits of WAKIX is that it has a very clean profile and it's able to be added on to many meds. As you heard, Dr. Dano, there wasn't a tremendous need to change therapies on these patients, though there may be some need for a select group of patients down the road. But WAKIX generally is well-tolerated and can generally be added on to many of the known therapies in the neurospace.
spk13: Thank you.
spk04: Our last question comes from Daniel Bro from Raymond Jeans.
spk07: Hey, guys. This is Alex. Hey, this is Alex. I'm for Danielle. Sorry, she couldn't make it. Hey, Alex. Good morning. So, yeah, I mean, as expected, you know, 3Q, we expect to be a bit softer. I mean, but you've still got the normal 300 net patient ads. I mean, should we expect a ramp-up from this 300 benchmarking 4Q looking forward? And if I could just tackle one more follow-up. Sorry if I missed it. Just appreciating more color on how new patients start compared to the last two quarters.
spk08: Thanks, Alex. Jeff Dirks, any comments on Alex's question?
spk09: Yeah, Alex, thanks very much for the question this morning. So with respect to how to think about new patient ads moving forward, I mean, certainly we're extremely pleased with our continued momentum, adding about 300 patients quarter over quarter. And although, again, we're not providing any forward-looking guidance on our business, we can kind of point you back to what we've accomplished in that normal seasonality that we've seen over the last couple of years. We have very strong top-line prescription demand. New patient starts has been relatively consistent, building on the momentum coming out of the second quarter. And as John shared earlier, we believe that there is still a large untapped remaining opportunity in narcolepsy. And we're very excited about our ability to continue to grow the brand and the underlying fundamentals moving forward. So hopefully those two pieces of information help with respect to how to think about our business moving forward as well as thinking about new patient ads from the third quarter and the second quarter. Thanks, Jeff.
spk07: Thanks, Alex. If I could see one more. Are you seeing any patterns in 4Q inventory stocking ahead of any, you know, expected new year price increases? If so, could you walk us through what, if any, inventory impact you expect for the upcoming quarter?
spk08: I mean, you know, generally you do see some increases in inventory, driven mostly due to just the holiday season. You'll see a couple of days, yeah, that happens typically in the quarter. And then that obviously reverses in Q1 as it has some of those impacts. But beyond that, there's not much I can share. It really will be variable depending on the time when the holidays fall, and those are other impacts as well. I would say nothing unusual, Ed. Yeah, nothing different from the other years.
spk07: Cool. Thanks so much. Thanks, Alex.
spk04: Thank you. I'm showing no further questions. This does conclude today's Harmony Biosciences third quarter 2022 financial results conference call. You may now disconnect your line and have a wonderful day.
spk08: Thank you, everybody.
Disclaimer